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ABSTRACT 
Recently, low serum concentrations of 25-hydroxyvitamin D [25(OH)D] have 
been linked to disturbances in glucose metabolism, development of type 2 diabetes, and 
increased risk of metabolic syndrome (MetS). Moreover, deficiency of vitamin D is now 
recognized to be highly prevalent in the U.S. and worldwide, impacting between 30% and 
50% of the general population. Therefore, the objective of this research study is to 
examine the associations between serum 25-hyroxyvitamin D and MetS. Data were 
collected from the Nutritional Interventions for Age-Related Muscular Function and 
Strength Losses Study. From this cohort, 186 independently living males and females 
over the age of 60, with vitamin D levels between 18 ng/mL and 30 ng/mL, without any 
existing liver or kidney disease or uncontrolled diabetes mellitus or type 1 diabetes 
mellitus requiring insulin, provided baseline data. A Pearson correlation coefficient of  
0.02 with non-significant p-value of 0.77 was found between MetS score and 25(OH)D. 
Factors such as average heart rate (p <0.05), weight (p <0.001) , BMI (p <0.001), 
LDL:HDL ratio (p <0.01), android fat (%) (p < 0.001), gynoid fat mass (p <0.001), and 
gynoid fat (%) (p <0.01) were found to have significant associations with the MetS score. 
A backwards stepwise regression indicated that android fat (%) (p <0.001), gynoid fat 
(%) (p = 0.001), total cholesterol (p <0.001), VLDL cholesterol (p <0.001), and 
LDL:HDL ratio (p <0.001) were most predictive of the MetS score. In conclusion, the 
major finding of this study was that the combination of android fat (%), gynoid fat (%), 
total cholesterol, VLDL cholesterol, and the LDL:HDL ratio were predictive of the MetS 
score. However, no significant association between low vitamin D status and prevalence 
of MetS could be established.
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CHAPTER 1.    INTRODUCTION 
The cluster of cardiovascular risk factors that define metabolic syndrome are 
important determinants of vascular disease and type 2 diabetes mellitus (T2DM), which 
are major causes of morbidity and mortality worldwide (1). Clinical diagnosis of 
metabolic syndrome (MetS) is based on the presence of three or more of the following 
markers of chronic disease: (i) greater waist circumference; (ii) elevated fasting plasma 
glucose (FG); (iii) hypertension referring to elevated systolic or diastolic blood pressure 
(SBP and DBP); (iv) elevated triglycerides (TG); and (v) low HDL cholesterol (2, 3). 
Recently, low serum concentrations of 25-hydroxyvitamin D or 25(OH)D have been 
linked to disturbances in glucose metabolism, development of type 2 diabetes, and 
increased risk of metabolic syndrome (4, 5, 6, 7, 8). Moreover, deficiency of vitamin D is 
now recognized to be highly prevalent in the U.S. and worldwide, impacting between 
30% and 50% of the general population (9). Traditionally, the most characterized 
consequence of vitamin D deficiency has involved the musculoskeletal system, leading to 
rickets in children, and osteomalacia or osteoporosis in adults. However, it is now 
recognized that vitamin D receptors are present on a large variety of cell types. This 
means that vitamin D metabolites regulate a very wide range of genes involved in overall 
and cardiovascular health. Studies in the U.S. and Europe show that most of the general 
population have 25(OH)D levels below the target level of 75 nmol/L, with levels being 
lower in those with MetS (1). Furthermore, prospective studies have shown that low 
25(OH)D levels are associated with increased all cause cardiovascular mortality. 
Therefore, it is vital to increase understanding and public knowledge on the importance 
of vitamin D status as it relates to chronic disease risk. The primary objective of this 
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research study was to determine whether low vitamin D status is associated with 
metabolic syndrome in males and females at least 60 years of age. My central hypothesis 
was that vitamin D status is inversely correlated with metabolic syndrome in a dose 
dependent manner. Data were collected from the Nutritional Interventions for Age-
Related Muscular Function and Strength Losses Study. From this cohort, 186 
independently living and primarily non-hispanic or latino white males and females over 
the age of 60, with vitamin D levels between 18 ng/mL and 30 ng/mL, without any 
existing liver or kidney disease or uncontrolled diabetes mellitus or type 1 diabetes 
mellitus requiring insulin, provided baseline data. 
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CHAPTER 2.    BACKGROUND 
Metabolic Syndrome 
In the United States, where nearly two-thirds of the population is overweight or 
obese, more than one-fourth of the population meets diagnostic criteria for metabolic 
syndrome (10). Unfortunately, this problem is further reaching than the U.S. alone. 
Approximately one-fourth of the adult European and Latin American population is 
estimated to have MetS. It is also considered to be an emerging epidemic in developing 
East Asian countries, including China, Japan, and Korea. It is clear that MetS is a major 
public-health and clinical challenge worldwide, bestowing a 5-fold increased risk of 
T2DM and 2-fold increased risk of developing cardiovascular disease (CVD) within 5-10 
years. 
The idea of MetS started as a concept rather than a diagnosis when a Swedish 
physician demonstrated the association of hypertension, hyperglycemia, and gout in the 
1920s (11). In 1947, it was identified that visceral obesity was commonly associated with 
the metabolic abnormalities found in CVD and T2DM. As the field moved forward, this 
cluster of risk factors for CVD and DM began to be described as “Syndrome X” by 
Reaven (1988), with the main focus being on insulin resistance. Obesity and visceral 
obesity were later added to the definition. Over the years the syndrome was renamed 
multiple times with varying definitions. More recently there has been controversy 
regarding the development of a single uniform definition of the disease. Currently, the 
most commonly used criteria for diagnosis are from the World Health Organization 
(WHO), the European Group for the study of Insulin Resistance (EGIR), the National 
Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), the American 
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Association of Clinical Endocrinologists (AACE), and the International Diabetes 
Federation (IDF). While each definition possesses common features, there are certain 
aspects that differ. The WHO, AACE, and EGIR are largely focused on evaluating 
insulin resistance and requires labor-intensive testing which is primarily performed in the 
research laboratory. The ATP III definitions use measurements and laboratory results that 
are readily available to physicians. For the purpose, of this study ATP III criteria were 
utilized for classification of disease. 
According to the ATP III report, MetS has been identified as a multiplex risk 
factor for cardiovascular disease that is deserving of more clinical attention (2). In the 
Framingham study, MetS alone predicted approximately 25% of all new-onset CVD. In 
addition, almost half of the population-attributable risk for diabetes could be explained by 
the presence of MetS. Diabetes was also shown to be a major risk factor for CVD. ATP 
III identifies abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin 
resistance and/or glucose intolerance, and pro-inflammatory and pro-thrombic states as 
six components of MetS. Beyond this, each risk factor is subjected to its own regulation 
through both genetic and acquired factors. This regulation of risk factors can be seen with 
low serum concentrations of 25(OH)D, which have been linked to disturbances in 
glucose metabolism. In addition, vitamin D receptors are present on a large variety of cell 
types, meaning that vitamin D metabolites likely regulate a very wide range of genes 
affecting many aspects of health, especially cardiovascular health.  
The current intervention for those with MetS is primarily a lifestyle modification 
that combines specific recommendations on diet and exercise with behavioral strategies. 
However, for those whose risk factors are not adequately reduced, pharmacological 
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interventions may be necessary (12). The clinical management of MetS is difficult 
because there is no recognized method to prevent or improve the whole syndrome. Thus, 
most physicians treat each component separately, with an emphasis placed on those that 
are easily treated with drugs due to the ease of prescribing a medication versus initiating 
a strategy to change people’s lives. Therefore, while intervention in any chronic disease 
is of great importance, prevention of this world wide epidemic should be at the forefront 
of discussion. Because MetS acts as a precursor to some of the leading causes of 
morbidity and mortality worldwide such as Type 2 diabetes and vascular disease it is of 
grave concern (1). Moreover, with much of the population worldwide having inadequate 
serum vitamin D, achieving adequate status of nutrients such as vitamin D could serve to 
have a profound global impact on health (9). 
Vitamin D Metabolism  
Vitamin D is a fat-soluble, cholesterol derived vitamin that can be obtained from 
synthesis by the skin following sun exposure, food, or supplements (9). Depending on the 
source, vitamin D can be acquired in one of two forms: vitamin D3 or vitamin D2. 
Vitamin D3 (cholecalciferol) is animal-derived and has high biological activity, whereas 
vitamin D2 (ergocalciferol) is plant-derived and therefore has lower biological 
availability. Vitamin D3 is formed from its precursor 7-dehydrocholesterol (DHC), which 
is found in abundant amounts in the skin of humans and animals. However, only a few 
foods naturally contain a significant amount of vitamin D3, which include: liver, fish liver 
oils, fatty fish, and egg yolks (13,14). Salmon, mackerel, and bluefish are excellent 
sources of D3, but it has been shown that farmed salmon has much less vitamin D3 than 
wild-caught salmon likely due to the food supply (47). Farmed salmon commonly receive 
a pelleted form of food that contains much less vitamin D than what wild salmon 
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consume in their natural habitiat. In addition, some countries including the  U.S., practice 
fortification of certain foods with vitamin D, such as milk products. Vitamin D2, on the 
other hand, is formed following exposure to UV radiation from its precursor ergosterol, 
which is present in plants, yeast, and fungi (14). 
The two forms of vitamin D are initially biologically inactive, and when in 
circulation require hepatic and renal metabolism in the liver and kidney in order to be 
bioavailable to cells (14, 15). After binding to a vitamin D carrier protein (DBP), vitamin 
D is transported to the liver, where it is enzymatically hydroxylated to 25(OH)D. 
25(OH)D synthesis is catalyzed by a microsomal cytochrome P450 enzyme (CYP2R1) to 
make 1,25(OH)D3. 25(OH)D then enters circulation where it has a half-life of about 15 
days. Normal circulating levels of 25(OH)D in the blood are between 25 nmol and 200 
nmol/L. Hydroxy vitamin D bound to DBP is then transported to the kidneys, where it is 
finally hydroxylated by CYP27B1 to generate the active form of 1,25(OH)D3. 
1,25(OH)D3 has a half-life of about 10-24 hours, and is tightly regulated by parathyroid 
hormone (PTH), calcium, phosphate, calcitonin, fibroblast GF 23, and [1,25(OH)D3] 
itself. 1,25(OH)D3 has biological effects such as increasing the resporption of calcium in 
the kidneys, but is also transported by DBP to other vitamin D receptor target tissues such 
as the bones, intestines, or parathyroid gland. 
1,25D functions as a hormone that, depending how much Ca is consumed in the 
diet and thus into the blood, works to maintain serum calcium (Ca) and phosphorus 
concentrations within the normal range by enhancing the ability of the small intestine to 
absorb these minerals from the diet (16). When dietary calcium intake is inadequate, 
1,25(OH)D3 along with PTH, withdraws calcium stores from the bone (3, 15). This 
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mechanism predominates in low Ca situations. In the kidney, 1,25(OH)D increases 
calcium reabsorption by the distal renal tubules. 
Vitamin D Status 
It is well established that vitamin D has important implications on our health, but 
the optimal intake of vitamin D remains a matter of debate. Much debate among 
researchers has centered around what concentrations of 25(OH)D or 1,25(OH)D are 
associated with deficiency (e.g., rickets), adequacy for bone health, and optimal overall 
health. Multiple forms of vitamin D exist, but serum concentrations of 25(OH)D are 
reflective of cutaneous vitamin D3 synthesis and dietary intake of vitamin D2 and D3 (13, 
14, 17, 18). Thus far, cut off values have not been agreed upon by consensus. However, 
the Institute of Medicine concluded that persons are vitamin D deficient if serum 
25(OH)D concentrations are <30 nmol/L (<12 ng/mL) (19). Vitamin D insufficiency is 
characterized by 25(OH)D < 50 nmol/L (12–20 ng/mL). The committee stated in their 
2008 report that 50 nmol/L is the serum 25(OH)D level that covers the needs of 97.5% of 
the population.  
Furthermore, intake reference values for vitamin D and other nutrients are 
provided in the Dietary Reference Intakes (DRIs) developed by the Food and Nutrition 
Board (FNB) at the Institute of Medicine of the National Academies (16) . DRIs describe 
a set of reference values used to plan and assess nutrient intakes of healthy people. These 
values, which vary by age and gender, include: 
Recommended Dietary Allowance (RDA): average daily level of intake sufficient 
to meet the nutrient requirements of nearly all (97% – 98%) healthy people (see Table 1). 
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Table 1. Recommended dietary allowances (RDAs) for vitamin D (16) 
Age Male Female Pregnancy Lactation 
0-12 months 400 IU 400 IU - - 
1-13 years 600 IU 600 IU - - 
14-18 years 600 IU 600 IU 600 IU 600 IU 
19-50 years 600 IU 600 IU 600 IU 600 IU 
51-70 years 600 IU 600 IU - - 
>70 years 800 IU 800 IU - - 
 
Vitamin D deficiency has recently come to light as being highly prevalent in the 
U.S. and worldwide (18). Vitamin D deficiency as it relates to bone health has previously 
been well established, and is characterized by inadequate mineralization, or by 
demineralization of the skeleton (18, 20). Among children, vitamin D deficiency is a 
common cause of rickets, whereas vitamin D deficiency in adults leads to a 
mineralization defect in the skeleton, causing osteomalacia, and  secondary 
hyperparathyroidism with osteoporosis.  
The 600 IU/day recommendation is currently based off  vitamin D levels deemed 
sufficient for bone health (48). However, if the body's sole input of vitamin D was only 
600 IU per day, that would likely not be enough to produce a value of even 10 ng/mL. It 
is a generally recognized that each additional 100 IU of vitamin D per day only raises 
serum 25(OH)D concentrations by approximately 1 ng/mL. It is also widely recognized 
that 600 IU/day of vitamin D produces barely perceptible changes in individuals who are 
overweight or obese, which is now over 50% of the U.S. adult population. Thus, the 
current RDA is likely not enough to prevent deficiency in many populations who are not 
receiving additional sunlight exposure, Therefore, an increase in the current 
recommendations may be warrented.  
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Furthermore, vitamin D regulates a wide range of genes that play a major role in 
cardiovascular and metabolic health. Recently vitamin D insufficiency has been shown to 
be associated with increased risk of developing T2DM and CVD, as well as metabolic 
syndrome (10, 21). While many studies back these findings, consistent results have not 
been well established in the literature. This is likely due to differences in geographic 
locations, skin pigmentation, age, health status, study size, population diversity, and 
seasonal variations. 
In an analysis of the Victorian Health Monitor survey in 2016, the associations 
between serum 25(OH)D, dietary calcium intake, and presence of the metabolic 
syndrome were examined (3). This analysis consisted of 3,404 participants without type 1 
or type 2 diabetes mellitus from Victoria, Australia. A higher serum 25(OH)D 
concentration was associated with significantly reduced odds of developing MetS.  In 
fact, for every 10 nmol/L increment that serum [25(OH)D] was reduced, the likelihood of 
MetS increased by 15%. Thus those in the highest levels of serum [25(OH)D] with 
concentrations between 65-204 nmol/L, were found to have a 60% lower chance of 
developing MetS. However, this was not statistically significant for every model of Ca 
intake tested, suggesting that vitamin D concentration can modulate the effect of Ca on 
MetS. It was observed that the overall effect of Ca at a moderate 25(OH)D level was 
stronger than at a low 25(OH)D level. This may be explained by the ability of 25(OH)D 
to maintain Ca homeostasis via active intestinal Ca absorption independent of its 
conversion to 1,25(OH)D3. Therefore, an improvement in vitamin D status from low to 
adequate would further increase intestinal Ca absorption.  
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Premenopausal women enrolled in the Womens’ Health Initiative-Calcium-
Vitamin D trial exhibited serum 25(OH)D concentrations that were inversely associated 
with serum triglyceride concentrations and the TG:HDL ratio (22). This same study also 
observed that serum 25(OH)D concentrations were inversely associated with adiposity 
after controlling for demographic and lifestyle risk factors, suggesting that vitamin D 
concentrations may contribute or be independently affected by adiposity. 
Role of Environment 
The major contributor to serum 25(OH)D concentrations for most humans is that 
synthesized by the skin after exposure to sunlight or artificial sources of UVB radiation 
between 280-320 nm (14, 21). Under normal circumstances this contributes to more than 
90% of the serum concentration of vitamin D in the human body. Furthermore, the 
photochemical reaction that takes place in the skin is most effective when the UVB 
radiation is at about 297 nm (18). This results in formation of pre-vitamin D3 from 7-
dehydrocholesterol in basal and suprabasal layers of the skin. The effectiveness of UVB 
on formation of pre-vitamin D3 in the skin is influenced by several UVB absorbing 
molecules (i.e., chromophores in the skin such as melanin, DNA, RNA, protein, and 7-
DHC). Experimental evidence indicates that about 50% of the pre-vitamin D3 can 
isomerize to vitamin D3 within 2.5 hours in the skin. Therefore, a rapid rise in vitamin D3 
levels is typically seen after exposure to UVB. Within 12-24 hours after UVB exposure 
the circulating concentration of vitamin D3 is at its maximal level. In fair skinned 
individuals, the maximum amount of vitamin D3 that can possibly be formed is 
synthesized within a few minutes of summer sun exposure (14). Longer exposures add 
nothing to vitamin D stores. In fact, maximal vitamin D synthesis occurs following 
suberthemeogenic UVB exposure, hence higher doses would cause conversion of pre-
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vitamin D3 to inactive isomers such as lumisterol, tachysterol, toxisterols, and 7-DHC. 
These high doses would also cause conversion of vitamin D3 to suprasterols and 5,6-
trans-vitamin D3 to prevent toxicity from too much sun exposure. 
The effectiveness of cutaneous synthesis of vitamin D is determined by: (i) the 
content of 7-DHC in the skin; (ii) the cutaneous concentrations of 7-DHC; (iii.) the 
energy of photons that depends on the wavelength of the UVB radiation; (iv) latitude, 
season, and time of day; (v) skin pigmentation; (vi) use of sunscreens (suppress 7-DHC); 
(vii) temperature (which regulates the conversion of pre-vitamin D3 to vitamin D3); (viii) 
exposure doses of UVB (maximal vitamin D synthesis occurs following subthermogenic 
UVB exposure, meaning that higher doses would cause conversion of pre-vitamin D3 to 
inactive isomers); and (ix) age-inverse relation between concentrations of 7-DHC in the 
epidermis with age (the body is less efficient at producing vitamin D as it gets older) (6, 
7, 8, 14). Factors such as air pollution often seen in urban environments can reduce 
exposure to sunlight as well (23). 
Role of Ethnicity 
In the United States, metabolic syndrome has a high prevalence in African 
Americans, particularly African American women (50). This has been attributed to the 
higher prevalence of obesity, hypertension, and diabetes in this population. However, the 
highest age adjusted prevalence of metabolic syndrome in the U.S. was found in Mexican 
Americans in a 1988-1994 NHANES survey. A major problem with the WHO and NCEP 
ATP III definitions of MetS has been their applicability to the different ethnic groups, 
especially when trying to define obesity cutoffs (49). This is particularly evident for the 
risk of T2DM, which is apparent at much lower levels of obesity in Asians compared to 
Europeans. As a solution to the variances in risk factors for different races and ethnicities, 
12 
the IDF proposed a set of criteria with racial/ethnic specific cut-offs. This accounts for 
the fact that the different populations, ethnicities, and nationalities have different 
distributions of norms for body weight and waist circumference as well as the variability 
in the relationship between these values and the risk for T2DM and CVD in different 
populations.  
Furthermore, ethnicity, skin tone, cultural practices, or occupation may  influence 
the amount of sun exposure and vitamin D produced. According to a study by Nair and 
Maseeh, ethnicity has consistently been reported to be related to circulating 25(OH)D 
concentrations in adults, and a high prevalence of hypovitaminosis D has been observed 
in several Indian studies (24). In another study of Maylay adults, female participants had 
significantly lower mean vitamin D levels than males after adjustment for age, central 
obesity, HDL cholesterol, and diastolic blood pressure (21). It was noted that possible 
contributing reasons could be explained by their clothing style, which consisted of long 
sleeves, long skirts, and a veil due to cultural or religious practices. Additionally, skin 
pigmentation plays a key role. Deeper skin tones absorb more UVB in the melanin of the 
skin than lighter-skinned individuals. Therefore, darker skinned individuals require more 
sun exposure to produce the same amount of vitamin D. Finally, in countries that do not 
fortify foods with vitamin D, intake is often lower than the already low amount consumed 
in the western diet. Therefore, supplementation of vitamin D may be essential in these 
areas of the world.  
Role of Aging 
Aging, even in healthy elderly people, is accompanied by a reduction in muscle 
mass and muscle strength, resulting in an increased risk of falls/fractures and need for 
increased assistance (12). Vitamin D deficiency is associated with muscle weakness, and 
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is common in elderly individuals. Older adults are at high risk of developing vitamin D 
insufficiency because of aging (21). Older adults cannot synthesize vitamin D as 
efficiently, and are more likely to spend more time indoors, have reduced skin thickness, 
are more likely to have inadequate dietary intakes of the vitamin, and experience 
impaired intestinal absorption, or impaired hydroxylation on the liver and kidneys. In a 
study of  824 elderly people aged >70 years from 11 European countries, 36% of men 
and 47% of women had wintertime serum 25(OH)D concentrations <30 nmol/L (53). 
Current available evidence indicates that vitamin D supplementation preserves muscle 
strength and functional abilities in high risk groups (21). Vitamin D metabolites have 
been found to affect muscle metabolism in 3 ways: 1) by mediating gene transcription, 2) 
through rapid pathways not involving DNA synthesis, and 3) by the allelic variant of the 
VDR. Vitamin D supplementation induces rapid changes in calcium metabolism of the 
muscle cell that cannot be explained by a slow genetic pathway. Evidence indicates that 
1,25(OH)D3, possibly through a vitamin D membrane receptor, acts directly on the 
muscle cell membrane (54, 55). Upon 1,25(OH)D3 binding, several interacting second-
messenger pathways were found to be activated in the muscle cell, resulting in enhanced 
calcium uptake (within minutes), both through voltage-dependent calcium channels and 
calcium release–activated calcium channels (56, 57, 58). A review of the literature 
regarding vitamin D deficiency on muscle function and falls in the eldery found that 
supplementation in this population improved muscle strength, walking distance, 
functional ability, and body sway (21). These findings and the observed improvements in 
bone density after vitamin D supplementation provide a partial explanation for the 
association between vitamin D supplementation and fewer falls and nonvertebral 
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fractures in elderly people. However, vitamin D deficiency is merely one condition that 
affects muscle function in elderly people, which is illustrated by the fact that even in 
healthy, vitamin D–replete, elderly people, muscle strength declined with age, which was 
not prevented by vitamin D supplementation (21).  
Furthermore, published data indicate that a statistically significant relationship 
exists between vitamin D and a variety of metabolic risk factors that can rise dramatically 
with age (2). During aging, the body has been observed to be less efficient at a variety of 
tasks, including cutaneous production of vitamin D, and regulation of blood pressure, 
weight status, insulin, and blood triglycerides, all of which may contribute to and increase 
the risk of developing MetS with age. 
Proposed Mechanisms 
The biological mechanism for the inverse associations between TG and the 
TG:HDL ratio is not completely understood, but it may be mediated by the effects of 
dietary calcium (22). Higher serum 25(OH)D increases the absorption of intestinal 
calcium which may bind to fatty/bile acids and form insoluble lipid-calcium complexes, 
thus inhibiting the absorption of cholesterol and increasing its fecal excretion. Another 
possibility is that there are reductions in hepatic TG synthesis or secretion in response to 
increased hepatocellular calcium concentrations (7, 22). Excess concentrations of PTH 
that are seen with low 25(OH)D could also play a part in these findings, as elevated PTH 
reduces lipolysis (7,22). The decreased peripheral removal of TG and 
hypertriglyceridemia has been observed in some states of hyperparathyroidism (22).  
Increased adiposity has consistently been associated with reduced serum 
25(OH)D concentrations and adverse cardiometabolic outcomes (6, 22, 24). Although the 
mechanism is not clear, it may be that overweight individuals at increased risk of 
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cardiometabolic disorders are more likely to have low serum 25(OH)D because of the 
high lipid solubility of serum 25(OH)D and sequestration by adipose tissue that results in 
reduced bioavailability. Alternately, it is possible that overweight individuals simply have 
less exposure to ultraviolet light due to lower levels of outdoor physical activity which 
results in lower serum 25(OH)D concentrations.  
The trend indicates that low vitamin D status may pose an increased risk of MetS; 
however the mechanisms proposed to explain this trend are less straightforward. A key 
feature in the pathophysiology of MetS is insulin resistance (3). 1,25(OH)D3 has a role in 
insulin secretion by stimulating the expression of the insulin receptor and increasing the 
responsiveness to glucose transport. During vitamin D deficiency, beta-cell function is 
inhibited, leading to a decrease in insulin secretion (3).  
The renin-angiotensin system is important in the regulation of blood pressure, 
another marker of MetS (3).  Low 25(OH)D concentrations may dysregulate control of 
the renin-angiotensin system. In fact, lower 25(OH)D concentrations have been found to 
be inversely correlated with measures of arterial stiffness and increased arterial 
resistance, HTN, and endothelial dysfunction. In a study by Kim et al., dosages of 
1,25(OH)D3 suppressed renin expression in mice indicating that blood pressure may 
influence the renin-angiotensin system (7). The suppression of renin likely inhibits the 
formations of angiotensin II, which increases salt retention and blood pressure by 
stimulating aldosterone secretion and increasing vasoconstriction. In addition, higher 
vitamin D status could reduce islet beta-cell damage by reducing islet renin-angiotensin 
system activity, thereby reducing the risk of developing hyperglycemia (3).  
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Moreover, there is evidence that Ca intake may influence fat balance and hence 
energy balance. Dietary Ca increases whole-body fat oxidation, which could potentially 
reduce circulating fatty acids/lipids. For an intake of 1,200 mg/d an increase of about 
5g/d in fecal fat can be expected (3). This arises from the interaction between non-
absorbed calcium and dietary fat in the gastrointestinal lumen which leads to Ca-fatty 
acid soap formation, and thus its eventual excretion. These outcomes may contribute to 
lower circulating TAG and other lipids seen with Ca supplementation (3).  
Finally, MetS is a chronic low-grade inflammatory state, and adequate vitamin D 
has a significant role in reducing inflammation in chronic disease (3). Low 25(OH)D and 
increases in PTH levels increase the risk of inflammation, as documented by elevated 
levels of C-reactive protein and interleukin-10 (51). Administration of 1,25(OH)D in a 
state of vitamin D deficiciency has been shown to down-regulate inflammatory 
biomarkers such as C-reactive protein (52). 
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CHAPTER 3.    SIGNIFICANCE AND INNOVATION 
Significance 
The published studies reviewed above indicate that a relationship may exist 
between vitamin D and a variety of metabolic risk factors. Perhaps more worrisome is 
that those risk factors can rise dramatically with age as the body becomes less efficient at  
producing cutaneous vitamin D and regulating blood pressure, weight, insulin, and 
triglycerides (2). This contributes in part to the increased prevalence of MetS in the aging 
population. Therefore, narrowing down possible contributors to such pathologies is of 
great importance. If an inverse relationship between [25(OH)D] and MetS can be 
established, physicians, dietitians, and the public may begin to take action in promoting 
sufficient vitamin D intake to prevent the onset of MetS and subsequent complications to 
reduce a major contributor to mortality and morbidity worldwide (20). 
Innovation 
While previous cohort studies evaluating the effect of vitamin D on metabolic 
syndrome have been performed, this study provides several key differences that will set it 
apart from previous counterparts. First, this study focuses on a population of men and 
women aged 60 and older. Few previous studies conducted have focused on the aging 
population, and several targeted only postmenopausal women. Additionally, there is a 
clear advantage to focusing on the older adult population, as several studies have 
demonstrated an age-related decline in many metabolic steps of the vitamin D pathway 
(16). This includes the rate of synthesis in the skin, the rate of hydroxylation, and the 
response of target tissues (e.g., bone). Therefore, it is likely that much of this population 
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is vitamin D deficient. Advancing age in general likely affects all levels of MetS 
pathogenesis and thus the prevalence of MetS rises with age (2). 
Furthermore, body composition changes that are associated with aging lead to 
increased adiposity and decreased muscle mass, making the diagnosis of obesity or 
increased adiposity challenging (25). In clinical practice and public health settings, 
anthropometric measures such as body mass index (BMI), waist circumference (WC), hip 
circumference (HC), waist-hip ratio (WHR), and more recently waist-height ratio 
(WHtR) are used as surrogates for intra-abdominal adiposity since they require little 
expense or time (15). Unfortunately, these measures are known to perform poorly in 
assessing the adiposity of certain populations such as older adults and body builders (26). 
More accurate methods such as DEXA, CT, or MRI are recommended for these groups.     
The distribution of fat affects the risks associated with obesity and the types of 
disease that result (17). Fat can be thought of as visceral adipose tissue (VAT) and 
subcutaneous adipose tissue (SAT), or as upper body (android or central) and lower body 
(gynoid or peripheral). SAT has been found to be innervated with a larger number of 
inflammatory and immune cells, and have a lesser pre-adipocyte differentiating capacity 
and a greater percentage of large adipocytes. Additionally, abdominal obesity, is a key 
feature of the atherothrombic and inflammatory abnormalities associated with MetS (27). 
There is substantial evidence linking central obesity with cardiovascular disease and the 
other MetS components. Therefore, it is advantageous to be able to distinguish between 
those at increased risk as a result of android obesity from those with the less serious 
gynoid fat distribution, in which fat is more evenly and peripherally distributed around 
the body. In other words, excess abdominal fat is generally an equal risk factor for 
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disease as is excess body fat in general (17). However, anthropometric measures are 
unable to distinguish fat versus lean mass or the amount, type, and distribution of adipose 
tissue. Waist circumference, the measure traditionally utilized in the diagnosis of MetS, is 
the simplest and most common way to measure abdominal obesity. It is the 
circumference of the abdomen, measured at the natural waist (in between the lowest rib 
and the top of the hip bone), the umbilicus (belly button), or the narrowest point of the 
midsection. While it is easy to measure, inexpensive, and strongly correlated with body 
fat in adults when measured accurately, the measurement procedure has not been 
standardized, and it may be difficult to measure. It is also less accurate in individuals 
with a BMI of 35 kg/m2 or higher. On the contrary, gold-standard methods of body 
composition analysis such as CT and MRI provide accurate whole-body and regional 
assessment of fat and muscle but are clinically impractical and costly for routine 
assessment (25). Therefore, it is more reasonable for accurate measurements of adiposity 
to be collected using DEXA in older adults. This can eliminate the challenges associated 
with using waist circumference as a clinical tool with its lack of diagnostic accuracy. 
DEXA works via X-ray beams that pass through different body tissues at varying rates. 
These low-level X-ray beams are then used to develop estimates of fat-free mass, fat 
mass, and bone mineral density (17). Compared to other imaging techniques, DEXA 
scanners are widely available, radiation exposure and patient burden is low, and cost is 
modest (28). Although DEXA cannot distinguish between intraabdominal and 
subcutaneous fat, in a study with a community-based elderly population, results 
suggested that android fat is more strongly associated with MetS than VAT (27). Adipose 
tissue in the android region quantified by DEXA has been found to have effects on 
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plasma lipid and lipoprotein concentrations, and it correlates strongly with abdominal 
visceral fat. Thus, DEXA is emerging as a new standard for body composition 
assessment due to its high precision, reliability, and repeatability. 
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CHAPTER 4.    RESEARCH DESIGN AND METHODS 
Methods 
This study was based on data collected during the Nutritional Interventions for 
Age-Related Muscular Function and Strength Losses Study funded by the National 
Institutes of Health and Metabolic Technologies Inc. and carried out by researchers at 
Iowa State University. Further demographic data are described in more detail elsewhere; 
in brief, participants of this study met the following requirements: (i) were male or 
female at least 60 years of age; (ii) were free from liver and kidney diseases; (iii) were 
free of a history of blood clots and/or taking blood thinner medication; (iv) provided no 
evidence of uncontrolled hypertension; (v)  had a body mass index (BMI) < 40 kg/m2; 
(vi) were not taking >1,000 IU of vitamin D supplement daily prior to participation in the 
study; (vii) were free of any serious acute or chronic medical condition or illness that 
would affect ability to exercise or calcium and bone metabolism; (viii) had no prior 
history of osteoporosis diagnosis; (ix) free of having a major surgery in past 6 weeks 
and/or a minor surgery in past 3 weeks at baseline; and (x) had no evidence of 
uncontrolled diabetes mellitus, or type 1 diabetes mellitus requiring insulin for glucose 
control. The data utilized in this analysis were collected between August 2014 and July 
2017, with participants recruited from the Des Moines and Ames, Iowa areas. 
Design 
This double blind randomized controlled trial design with a 1 year follow-up 
period is described in more detail elsewhere, but for the purpose of this study it is briefly 
outlined here. Participants meeting the above criteria were randomized into one of four 
treatments. Group 1 received the dietary placebo plus exercise program, group 2 received 
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the dietary placebo without exercise, group 3 received 2,000 IU of vitamin D + HMB 3.0 
g/day without the exercise program, and group 4 received 2,000 IU vitamin D + HMB 3.0 
g/day plus the exercise program. The exercise program consisted of a monitored strength 
training program 3 times per week for 1 year. 
Measurements 
Of the 235 males and females aged ≥ 60 years screened for the Nutritional 
Interventions for Age-Related Muscular Function and Strength Losses Study, 186 
individuals provided baseline data consisting of: (i) height, weight, and BMI (Body Mass 
Index, kg/m2); (ii) vital signs (heart rate and blood pressure); (iii) 30 mL of blood for a 
fasted baseline biochemical profile (glucose, calcium, blood lipid profiles, liver enzymes, 
and vitamin D status); (iv) a urinalysis; (v) body composition analysis including DEXA, 
BodPod, and BIA analyses as well as elbow breadth measurements; (vi) health, medical 
history, and subject information based off questionnaires; (vii) an assessment of 
functional mobility, balance, and agility using an Up-&-Go test and Get-Up test; (viii) 
and strength measurements provided by biodex testing and hand-grip strength analyses. 
While individuals were followed for a 1-year period with testing every 3 months, only 
baseline data will be utilized in this study as to not interfere with any current ongoing 
investigations.  
Definition of Metabolic Syndrome 
Slight variances exist for defining levels of criteria for clinical diagnosis MetS, 
but for the purposes of this study MetS was defined according to the most recent 
statement by the National Cholesterol Education Program Adult Treatment Panel III 
(NCEP-ATP III) criteria (10). According to this statement an individual with MetS must 
meet three or more of the following criteria: triglycerides ≥150 mg/dL, low HDL 
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cholesterol (Men <40 mg/dL and Women <50 mg/dL), elevated blood pressure ≥130/ 
≥85 mmHg, abnormal fasting glucose ≥110 mg/dL, and abdominal obesity, given as 
waist circumference (Men >102 cm (40 in) and Women >88 cm (35 in). Waist 
circumference cut-offs were developed to identify abdominal obesity based on a series of 
studies in Caucasians. These cut-offs were not chosen based on risk factors, but rather 
their relation to BMI (29). Two action levels for waist circumference were developed in 
which a BMI >25 kg/m2 (action level 1) translated to 94 cm for men and 80 cm for 
women, and a BMI >30 kg/m2 (action level 2) translated to 102 cm for men, and 88 cm 
for women (30). In order to obtain a standardized cut off  for abdominal obesity using 
DEXA measurements, the mean of NHANES 2005-2006 examination data on android fat 
mass was 1,719 g. Thus anything greater than this amount is considered to be a risk factor 
for MetS (31). 
Data Analysis 
The aim of the current study was to identify determinants of MetS in older adults.  
Therefore, the main outcome variable was the status, or degree of MetS as characterized 
by the MetS Score. Multiple risk factors comprise MetS; however, the typical diagnosis 
supplies only a yes or no answer regarding whether and individual has it. A large 
contribution of this study was to propose a MetS score that characterizes the degree of 
severity each subject suffers from the syndrome. The MetS score was developed using 
Microsoft Excel. Standardized z-scores and percentile rankings for each participant were 
calculated based off data from the CoLaus Study (32). Percentile rankings ranging from 
the 1st percentile to the 99th percentile for SBP, DBP, android fat mass, FG, TG, and HDL 
were summed together to create a score ranging from 6-594. Further statistical analyses 
were conducted using SigmaPlot 11.0 software. A Pearson correlation was estimated for 
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a number of demographic and metabolic variables to determine strength of linear 
association. These results are represented in Tables 6A and 6B; a p-value <0.05 was 
considered statistically significant. A two-sample t-test was performed to compare 
characteristics between groups of men and women, as well as those with MetS versus 
those without. An additional t-test was performed to evaluate seasonal variation within 
the group. Participants who underwent baseline testing between the months of November 
and February were arbitrarily coded as 0 and those between the months of March and 
October were coded as 1. Finally, three backwards step-wise regression analyses were 
performed. Models 1, 2, and 3 included MetS score as the dependent variable, whereas 
Model 4 included serum 25(OH)D as the dependent variable. 
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CHAPTER 5.    RESULTS 
Demographic characteristics of the sample are show in Table 2. Of the 186 
participants providing baseline data, gender was split almost evenly, with 54.8% of 
participants being males and 46.2% being females. Of those men and women, an 
overwhelming majority were non-Hispanic white or Latino individuals. The remainder of 
the sample consisted of 1% whom identified as Asian, 1% as black or African-American, 
2% Hispanic, and 4% were of an unreported or unknown race and/or ethnicity.  
Table 2. Demographic characteristics of sample  
  Number (%) 
Characteristic   
Age (n = 186)  60-69 
70-79 
80+ 
128 (69) 
52 (28) 
6 (3) 
Sex (n = 186) Female 
Male 
84 (46.8) 
102 (54.2) 
Race White 
Asian 
Black/African-American 
Unknown 
180 (97) 
2 (1) 
2 (1) 
2 (1) 
Ethnicity Non-Hispanic or Latino 
Hispanic 
Not reported 
Unknown 
177 (95) 
4 (2) 
4 (2) 
1 (1) 
 
Anthropometric and metabolic characteristics of the study population are given in 
Table 4 and Table 5. The mean age of the population was about 67 years and was shown 
to be relatively constant regardless of gender or MetS diagnosis. As expected, metabolic 
indicators tended to increase as the number of risk factors for MetS increased. It is 
important to note that in the case of fat distribution, those with the lowest amount of risk 
factors had a lower total amount of both android and gynoid fat mass, but tended to have 
a higher percent of gynoid fat distribution. This indicates that those with less risk factors 
for MetS tended to have less central adiposity, or in other words tended to have a “pear” 
26 
shaped distribution of body fat rather than an “apple” shape. This finding agrees with 
previous literature that central adiposity is linked to MetS (27, 28). 
Furthermore, blood calcium measurements were extremely stable across all levels 
of MetS. This can be explained mechanistically; when the calcium in our blood drops too 
low, the parathyroid glands make more PTH. Increased PTH in turn stimulates the bones 
to release calcium into the blood resulting in stable blood calcium levels. Therefore, 
while calcium measurements were constant across all levels, PTH levels increased with 
the increasing number of risk factors indicating that those with more risk factors for MetS 
had lower levels of circulating blood Ca and thus relied more heavily on Ca drawn from 
bone stores. Serum 25(OH)D levels were also relatively constant across all levels of 
MetS, and could be a result of the small range of vitamin D status within our sample.  
Further group differences between those with and without MetS, as determined by 
having 3 or more of the 5 previous mentioned risk factors, were evaluated using a two 
sample t-test. Android fat mass, fasting glucose, blood pressure, and triglycerides were all 
found to be lower, while HDL cholesterol levels were found to be higher in those without 
MetS. Statistically significant differences (p <0.001) were recorded for all risk factors 
except for blood pressure and serum 25(OH)D levels.  
Characteristic comparison between genders resulted in finding a much larger 
number of women without MetS (n = 65) than with MetS (n= 19), whereas men were 
more evenly distributed at 50 and 52 respectively. Another finding worth noting is that 
men tended to have higher central obesity than women regardless of MetS diagnosis. 
Furthermore, two-sample t-tests indicated that statistically significant differences existed 
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between males and females when comparing android fat mass and HDL cholesterol levels 
p <0.001 and p <0.004 were reported.  
To investigate further the 25(OH)D levels within the population an additional two 
sample t-test was performed comparing those with vitamin D levels below and above 25 
ng/mL. Of the 186 participants, 99 had vitamin D levels below 25 ng/mL and 87 had 
levels at or above 25 ng/mL. No significant differences betweetn groups was significant 
for any of the risk factors of MetS. 
Pearson correlation coefficients between anthropometric measures or metabolic 
characteristics are shown in Tables 6A and 6B. No association was found between MetS 
score and serum 25(OH)D levels. Factors such as average heart rate, weight, BMI, 
LDL:HDL ratio, android fat (%), gynoid fat mass, and gynoid fat (%) were found to have 
significant associations with the MetS score. When evaluating these findings it should be 
taken into consideration that android fat mass, total cholesterol, and HDL cholesterol 
comprise part of the MetS score.  
To identify the strongest predictors of the MetS score, a backwards stepwise 
regression model was estimated. Table 7A shows results from Model 1 which includes 
only the 5 risk factors that comprise the MetS score. This regression model demonstrates 
that DBP, FG, and HDL cholesterol were most highly predictive of the overall MetS 
score. Table 7B (Model 2) includes several anthropometric measures and metabolic 
outcomes as well as the risk factors for MetS as independent variables. Because of the 
problem of endogeneity, it was not surprising to find that many of these variables as part 
of the final predictive equation, and resulted in a high R2  value of 0.88, indicating that 
this model highly predictive of the MetS score. However, because MetS is comprised of 
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these five risk factors, the final model (Model 3) did not include them as independent 
variables. Thus android fat (%), gynoid fat (%), total cholesterol, VLDL cholesterol, and 
the LDL:HDL ratio were found to be most predictive of the MetS score, with an R2  value 
of 0.46. Again, due tho the problem of endogenity between a variety of risk factors, 
another model was ran leaving out any interrelated risk factors that could contribute to 
the MetS score to be certain that Model 3 was in fact accurate. We found that even once 
any interrelated factors were left out, no other factors such as serum vitamin D, PTH, or 
Ca were left. Thus, we concluded that Model 3 was in fact an accurate prediction of the 
MetS score. 
The season in which blood measurements were performed did not appear to 
influence serum vitamin D levels. A two-sample t-test evaluating those with baseline data 
collected in low sun months (November through February) compared to those with 
baseline data collected in high sun exposure months (October through March) concluded 
that there was no significant difference between serum vitamin D levels in either group.  
 
Table 3. Criteria for metabolic syndrome among adults aged ≥ 60 years. 
               
 Total  MetS  No MetS  
Number (%) 186 (100) 114 (61) 72 (39) 
Criterion    
Android Fat Mass 
(>1718.94 g) 
163 (87.6) 91 (79.8) 72 (100) 
HDL 
(M <40; F <50 mg/dl) 
49 (26.3) 7 (6.1) 42 (58.3) 
TG   
(≥150 mg/dl) 
55 (29.6) 6 (5.3) 49 (68) 
Fasting Glucose (>110 
mg/dl) 
32 (17.2) 6 (5.3) 26 (36.1) 
Blood Pressure 
(≥130/85 mm/Hg) 
140 (75.3) 76 (66.7) 63 (87.5) 
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Table 4. Baseline characteristics of participants classified by MetS diagnosis and stratified by the number of risk factors (RF) present  
 Total 
(n=186)  
No MetS 
(n=114) 
 
MetS 
(n=72) 
0 RF 
(n=6) 
1 RF 
(n=30) 
2 RF 
(n=78) 
3 RF 
(n=39) 
4 RF 
(n=27) 
5 RF 
(n=6) 
Age 67 ± 5 68 ± 5 68 ± 6 64 ± 3 69 ± 6 67 ± 5 69 ± 6 67 ± 5 71 ± 5 
HR (bpm) 65 ± 12 64 ± 11 65 ± 13 64 ± 8 64 ± 7 64 ± 13 65 ± 10 65 ± 17 65 ± 9 
SBP (mmHg) 140 ± 20 138 ± 22 143 ± 16 117 ± 10 129 ± 18 143 ± 23 144 ± 15 140 ± 15 146 ± 27 
DBP (mmHg) 78 ± 11 77 ± 12 80 ± 10 67 ± 7 74 ± 8 79 ± 13 80 ± 9 81 ± 11 79 ± 10 
Height (cm) 170.8 ± 10.1 169.5 ± 10.7 172.8 ± 8.7 162.2 ± 7.5 166.1 ± 10.4 171.5 ± 10.5 172.8 ± 9 172.9 ± 8.8 172 ± 7.2 
Weight (kg) 85.1 ± 17.9 80.3 ± 19.0 92.6 ± 12.9 61.8 ± 7.8 72.7 ± 17.2 84.9 ± 18.5 91.7 ± 12.3 92.3 ± 13.0 99.5 ± 15.8 
BMI (kg/m2) 29.0 ± 6.6 27.8 ± 5.1 31.0 ± 4.0 24.1 ± 2.4 26.2 ± 5.0 28.7 ± 5.1 30.8 ± 4.3 30.9 ± 3.6 33.5 ± 4.0 
   Android (kg) 3.1 ± 1.1 2.8 ± 1.2 3.5 ± 0.9 1.4 ± 0.2 2.3 ± 1.0 3.1 ±1.1 3.4 ± 0.9 3.4 ± 0.9 3.8 ± 1.0 
    Gynoid (kg) 5.3 ± 1.5 5.2 ± 1.6 5.4 ± 1.4 4.3 ± 0.7 5.0 ± 1.6 5.4 ± 1.6 5.5 ± 1.7 5.1 ± 1.0 6.0 ± 1.3 
Android (%) 44 ± 7 43 ± 7 46 ± 5 36 ± 6 41 ± 8 45 ± 6 46 ± 6 46 ± 5 47 ± 4 
   Gynoid (%) 41 ± 7 42 ± 8 40 ± 7 44 ± 6 44 ± 7 41 ± 8 40 ± 8 39 ± 6 43 ± 7 
TC (mg/dL) 203 ± 39 204 ± 35 201 ± 44 225 ± 53 205 ± 31 202 ± 35 202 ± 42 206 ± 47 176 ± 46 
LDL (mg/dL) 188 ± 34 118 ± 31 118 ± 38 137 ± 49 118 ± 25 117 ± 32 119 ± 32 123 ± 44 87 ± 26 
VLDL (mg/dL) 25 ± 12 20 ± 9 34 ± 13 17 ± 8 19 ± 6 20 ± 9 29 ± 13 38 ± 10 45 ± 7 
 HDL (mg/dL) 59 ± 18 66 ± 18 48 ± 12 72 ± 14 69 ± 17 65 ± 19 53 ± 12 45 ± 12 32 ± 5 
LDL:HDL 2.2 ± 0.8 1.9 ± 0.8 2.5 ± 0.8 2.0 ± 1.0 1.8 ± 0.7 2.0 ± 0.8 2.3 ± 0.8 2.8 ± 0.8 2.8 ± 0.7 
TG (mg/dL) 127 ± 65 98 ± 43 174 ± 68 83 ± 30 92 ± 28 101 ± 43 150 ± 65 189 ± 65 259 ± 88 
FG (mg/dL) 100 ± 16 96 ± 9   108 ± 22 91 ± 8 94 ± 8 97 ± 9 100 ± 13 115 ± 29 126 ± 15 
    25D(ng/mL) 23.8 ± 4.1 23.9 ± 4.2 23.7 ± 4.1 24.8 ± 3.3 23.1 ± 4.1 24.2 ± 4.3 24.7 ± 3.8 22.9 ± 4.1 21.1 ± 4.5 
PTH (pg/mL) 45.5 ± 20.5 43.6 ± 17.5 48.8 ± 24.5 35.2 ± 5.2 42.0 ± 15.8 44.9 ± 18.6 43.6 ± 24.2 51.9 ± 22.7 56.7 ± 20.2 
Ca (mg/dL) 9.4 ± 0.3 9.4 ± 0.3 9.4 ± 0.3 9.4 ± 0.3 9.3 ± 0.3 9.4 ± 0.4 9.3 ± 0.3 9.48 ± 0.3 9.4 ± 0.3 
Data are expressed as means ± standard deviations. Abbreviations: HR (heart rate), SBP (average systolic blood pressure), DBP (average diastolic blood pressure), BMI (body 
mass index), TC (total cholesterol), LDL (low density lipoprotein), VLDL (very low density lipoprotein), HDL (high density lipoprotein), TG (triglycerides), FG (fasting glucose), 
25D (25-hydroxy vitamin D), PTH (parathyroid hormone), Ca (calcium). 
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Table 5. Baseline characteristics of participants classified by gender 
 Female 
(n=84) 
Male 
(n=102) 
Females No MetS 
(n=65) 
Females MetS 
(n=19) 
Males No MetS 
(n=50) 
Males MetS 
(n=52) 
 
Age 68 ± 6 68 ± 5 68 ± 6 69 ± 6 67 ± 5 68 ± 5 
HR (bpm) 66 ± 11 63 ± 12 65 ± 12 70 ± 7 63 ± 9 63 ± 14 
SBP (mmHg) 139 ± 25 140 ± 16 137 ± 27 147 ± 13 139 ± 14 141 ± 17 
DBP (mmHg) 78 ± 13 79 ± 10 76 ± 14 83 ± 9 79 ± 9 79 ± 10 
Height (cm) 162.7 ± 6.2 177.4 ± 7.5 162.6 ± 6.4 163.1 ± 5.6 178.4 ± 8.3 176.5 ± 6.5 
Weight (kg) 74.1 ± 15.0 94.1 ± 14.7 70.4 ± 13.4 86.4 ± 13.9 93.0 ± 17.5 95.2 ± 11.5 
BMI (kg/m2) 28.1 ± 5.6 39.9 ± 4.3 26.7 ± 5 32.6 ± 5.3 29.2 ± 5 30.6 ± 3.4 
Android Fat (kg) 2.7 ± 1.1 3.4 ± 1.1 2.3 ± 1.0 3.4 ± 1.0 3.3 ± 1.2 3.5 ± 0.9 
Gynoid Fat (kg) 5.7 ± 1.7 4.9 ± 1.3 5.4 ± 1.6 6.6 ± 1.6 4.9 ± 1.3 4.9 ± 1.1 
Android Fat (%) 45 ± 7 43 ± 6 44 ± 7 50 ± 4 42 ± 7 44 ± 5 
Gynoid Fat (%) 47 ± 5 36 ± 5 47 ± 6 50 ± 4 36 ± 6 36 ± 4 
TC (mg/dL) 202 ± 34 203 ± 42 201 ± 35 206 ± 31 207 ± 34 200 ± 48 
LDL (mg/dL) 115 ± 29 121 ± 37 115 ± 31 116 ± 23 122 ± 32 119 ± 42 
VLDL (mg/dL) 24 ± 11 26 ± 13 20 ± 8 35 ± 14 19 ± 10 33 ± 12 
          HDL (mg/dL) 64 ± 19 56 ± 17 66 ± 20 54 ± 14 66 ± 16 46 ± 11 
LDL:HDL 2.0 ± 0.7 2.3 ± 0.9 1.9 ± 0.7 2.3 ± 0.7 2.0 ± 0.8 2.6 ± 0.8 
TG (mg/dL) 117.7 ± 56.0 134.6 ± 71.4 100.6 ± 37.3 176.3 ± 69.6 96.4 ± 52.1 171.4 ± 52.6 
FG (mg/dL) 100.2 ± 17.9 100.5 ± 14.8 95.9 ± 10.0 115.1 ± 28.7 96.4 ± 8.9 104.4 ± 18.1 
25(OH)D (ng/mL) 23.8 ± 4.1 23.9 ± 4.2 23.6 ± 4.1 24.3 ± 4.2 24.2 ± 4.3 23.6 ± 4.1 
PTH (pg/mL) 41.4 ± 14.4 48.6 ± 23.6 41.5 ± 14.5 41 ± 14.6 46 ± 20.4 51.1 ± 26.5 
Ca (mg/dL) 9.4 ± 0.4 9.4 ± 0.3 9.4 ± 0.4 9.3 ± 0.4 9.4 ± 0.3 9.4 ± 0.3 
Data are expressed as means ± standard deviations. Abbreviations: HR (heart rate), SBP (average systolic blood pressure), DBP (average diastolic blood 
pressure), BMI (body mass index), TC (total cholesterol), LDL (low density lipoprotein), VLDL (very low density lipoprotein), HDL (high density lipoprotein), 
TG (triglycerides), FG (fasting glucose), PTH (parathyroid hormone), Ca (calcium). 
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Table 6A. Correlation coefficients between MetS Score and a variety of anthropomentric and metabolic risk factors 
 MetS Age Height Weight BMI HR SBP DBP FG TG 
MetS Score --          
Age 0.11 --         
Height (cm) -0.02 -0.10 --        
Weight (kg) 0.29*** -0.001 0.59*** --       
BMI (kg/m2) 0.38*** 0.04 -0.006 0.55*** --      
HR (bpm) 0.16* 0.07 -0.01 0.06 0.02 --     
SBP (mmHg) 0.12 0.25*** 0.01 0.05 0.01 0.12 --    
DBP (mmHg) 0.13 -0.09 0.09 0.18 0.07 0.25*** 0.57*** --   
FG (mg/dL) 0.36*** 0.11 -0.008 0.06 0.03 0.11 0.04 0.05 --  
TG (mg/dL) 0.57*** -0.001 0.08 0.24** 0.20* -0.06 -0.09 -0.09 0.31*** -- 
TC (mg/dL) 0.13 -0.07 -0.03 -0.07 0.06** -0.10 -0.04 -0.04 -0.09 0.14* 
LDL (mg/dL) -0.03 -0.11 0.02 -0.08 0.04 -0.13 -0.07 -0.06 -0.08 0.07 
VLDL (mg/dL) 0.07 -0.009 0.06 0.20** 0.18 0.06 -0.12 -0.09 0.32*** 0.99*** 
HDL (mg/dL) -0.48*** 0.05 -0.15* -0.17* -0.09 0.06 0.12 0.09 -0.26*** -0.5*** 
LDL:HDL -0.22** -0.12 0.12 0.06 0.09 -0.14 -0.14 -0.1 0.11 0.45*** 
25(OH)D (ng/mL) -0.02 -0.04 -0.004 0.08 0.12 0.05 0.01 -0.05 -0.19* -0.03 
PTH (pg/mL) 0.03 0.10 0.12 0.10 -0.02** -0.06 0.10 -0.03 0.04 0.12 
Ca (mg/dL) 0.09 0.14 -0.04 -0.004 0.01 0.03 0.63 -0.02 0.18* 0.12 
Android (g) 0.28*** 0.01 0.34*** 0.80*** 0.51 0.03 0.09 0.18* 0.07 0.24** 
Gynoid (g) 0.34*** -0.002 -0.03 0.51*** 0.46*** 0.15* 0.01 0.11 -0.03 0.02 
Android (%) 0.47*** -0.03 -0.11 0.39*** 0.42*** -0.03 0.04 0.13 0.09 0.17 
Gynoid (%) 0.20** 0.03 -0.51*** -0.11 0.20*** 0.15 -0.06 -0.01 -0.04 -0.11 
*p < 0.05. **p < 0.01. ***p < 0.001. Abbreviations: BMI (body mass index), HR (heart rate), SBP (average systolic blood pressure), DBP (average diastolic 
blood pressure), FG (fasting glucose), TG ( triglycerides), TC (total cholesterol), LDL (low density lipoprotein), VLDL (very low density lipoprotein), HDL 
(high density lipoprotein), PTH (parathyroid hormone), Ca (calcium). 
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Table 6B. Correlation coefficient between MetS Score and a variety of anthropometric and metabolic risk factors 
 TC LDL VLDL HDL LDL:HDL 25(OH)D PTH Ca Andriod 
Mass 
Gynoid 
Mass 
Android 
% 
TC (mg/dL) --           
LDL (mg/dL) 0.92*** --          
VLDL (mg/dL) 0.11 0.05 --         
HDL (mg/dL) 0.33*** 0.04 -0.53*** --        
LDL:HDL 0.43*** 0.67*** 0.43*** -0.63*** --       
25(OH)D (ng/mL) -0.06 -0.10 0.04 0.14 -0.13 --      
PTH (pg/mL) -0.11 -0.11 0.13 -0.11 0.04 -0.36*** --     
Ca (mg/dL) 0.13 0.08 0.17* 0.39 0.01 0.04 -0.14 --    
Android (g) -0.04 -0.07 0.19** -0.13 0.03 -0.01 0.09 -0.04 --   
Gynoid (g) -0.06 -0.13 -0.003 0.08 -0.16* 0.06 -0.02 -0.06 0.96*** --  
Android (%) 0.01 -0.04 0.14 -0.03 -.001 -0.07 0.47 0.01 0.96*** 0.98*** -- 
Gynoid (%) -0.05 -0.13 -0.11 0.22** -0.24** -0.02 -0.09 -0.05 0.92*** 0.98*** 0.99*** 
*p < 0.05. **p < 0.01. ***p < 0.001. Abbreviations: TC (total cholesterol), LDL (low density lipoprotein), VLDL (very low density lipoprotein), HDL (high 
density lipoprotein), PTH (parathyroid hormone), Ca (calcium). 
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Table 7A. Backwards stepwaise regression analysis predicting MetS score (Model 1) 
Dependent Variable Independent Variable Coefficient Std. Coefficient  Std. Error p-value 
MetS Score Average SBP 0.99 0.30  0.14  <0.001 
 Average DBP 1.98 0.33 0.26 <0.001 
 Android Fat Mass 0.03 0.44 0.002 <0.001 
 Fasting Glucose 1.08 0.26 0.15 <0.001  
 HDL Cholesterol 1.27 0.34 0.15 <0.001 
 Triglycerides 0.29 0.27 0.04 <0.001 
Final Equation: MetS score = -305.00 + (0.99 SBP) + (1.98 DBP) + (0.03 Android fat) + (1.08 FG) + (1.27 HDL) + (0.29 TG)    
        
 
Table 7B. Backwards stepwaise regression analysis predicting MetS score (Model 2) 
Dependent Variable Independent Variable Coefficient Std. Coefficient  Std. Error p-value 
MetS Score Average SBP 1.40 0.38  0.13  <0.001 
 Average DBP 2.57 0.38 0.24 <0.001 
 Android Fat Mass 0.03 0.39 0.01 <0.001 
 Fasting Glucose 0.85 0.22 0.15 <0.001  
 Average Height -0.86 -0.13 0.40 0.033 
 Average Weight 0.97 0.25 0.49 0.051 
 Gynoid Fat Mass -0.01 -0.27 0.01  0.036 
 Gynoid % Fat  2.19  0.24 1.06 0.042 
 Total Cholesterol 0.44 0.25 0.05 <0.001 
 VLDL Cholesterol 1.38 0.23 0.26 <0.001 
 LDL:HDL Ratio -26.67  -0.33 3.52  <0.001 
Final Equation: MetS score = -297.97 + (1.40 SBP) + (2.57 DBP) + (0.03 Android fat) + (0.85 FG) + (-0.86 Ht.) + (0.97 Wt.) + (-0.01 Gynoid %) + (0.44 TC) + 
(1.38 VLDL) + (-26.67 LDL:HDL)                    R2:0.88 
The following variables did not significantly add to the ability of the equation to predict MetS Sscore adnwere not indluced in the final equation: age, TG, HDL 
cholesterol, average HR, BMI, android % fat, LDL cholesterol, serum PTH,  calcium, serum 25(OH)D. 
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Table 7C. Backwards stepwise regression analysis predicting MetS score (Model 3) 
Dependent Variable Independent Variable Coefficient Std. Coefficient  Std. Error p-value 
MetS Score Android Fat (%) 6.87 0.61 0.93  <0.001 
 Gynoid Fat (%) -2.55  -0.28  0.77 0.001 
 Total Cholesterol  0.49 0.28 0.13 <0.001 
 VLDL Cholesterol 2.02  0.33 0.48  <0.001 
 LDL:HDL -43.4 -0.54 7.10 <0.001 
Final Equation: MetS score = 33.44 + (6.87 Android Fat %) + (-2.55 Gynoid Fat %) + (0.49 TC) + (2.02 VLDL) + (-43.41 LDL:HDL)                     R2:0.46                            
 
The following variables did not significantly add to the ability of the equation to predict MetS score and were not included in the final equation: age, average HR, 
average height, average weight, BMI, gynoid fat mass, LDL cholesterol, serum PTH, calcium, and serum 25(OH)D. 
 
 
 
 
Table 8. Backwards stepwise regression analysis predicting serum 25(OH)D levels 
Dependent Variable Independent Variable Coefficient Std. Coefficient  Std. Error p-value 
Serum 25(OH)D Android Fat Mass -0.002 -0.55  0.001  0.002 
 Average Height 0.08  0.21  0.04  0.031 
 BMI 0.52 0.60 0.15  <0.001 
 PTH -0.07  -0.36  0.02  <0.001 
Final Equation: Serum 25(OH)D = 4.20 (-0.002 Android Mass) + (0.08 Ht.) + (0.52 BMI) + (-0.07 PTH)                                                                    R2: 0.21      
 
The following variables did not significantly add to the ability of the equation to predict serum 25(OH)D and were not included in the final equation: MetS score, 
age, average DBP, FG, TG, HDL cholesterol, average HR, average weight, gynoid fat mass, android % fat, gynoid % fat, TC , VLDL cholesterol, LDL 
cholesterol, LDL:HDL, and calcium.
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CHAPTER 6.    DISCUSSION 
The major finding in this study was that the combination of android fat (%), 
gynoid fat (%), total cholesterol, VLDL cholesterol, and the LDL:HDL ratio were 
predictive of the MetS score with a multiple regression coefficient of 33.44 and a 
standard error of the estimate of 50.34 (Model 3). While there is a certain extent of 
interrlatedness between the risk factors that comprise the MetS score and the independent 
variables that were found to be predictive of MetS, it is worth noting that body fat 
appears to play an important role in predicting MetS.  
Vitamin D was excluded from the model and therefore the hypothesis that vitamin 
D status would explain a significant portion of the variance in MetS was rejected. 
However, the android fat mass, average height, BMI, and PTH were all predictive of 
serum 25(OH)D in a stepwise backward regression model. Previous literature has 
indicated that large amounts of fat mass could lead to sequestration of the fat soluble 
vitamin D, and thus lower serum 25(OH)D concentrations (6, 22, 24). The finding that 
android fat mass, but not gynoid fat mass was predictive of 25(OH)D takes this a step 
further by indicating that distribution of fat may be more predictive of health outcomes 
than just fat mass alone. 
Therefore, while no significant correlation between vitamin D and MetS score was 
detected, previous literature has demonstrated obesity and low HDL levels to be 
associated with vitamin D deficiency, in fact the risk of vitamin D deficiency was almost 
double among obese adults compared to normal weight adults (40). Similar findings have 
been reported worldwide. Research on 3,100 women in northeast Scotland found that 
those with an average BMI of 34 kg/m2 produced 10% less vitamin D than those of 
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average weight (41). In Spain it was reported that that over half of those with a BMI ≥ 40 
kg/m2 were diagnosed with vitamin D deficiency (42). BMI was also significantly 
correlated with 25(OH)D concentrations after adjusting for insulin-sensitivity, HDL 
cholesterol, LDL cholesterol, total cholesterol, and triglycerides in a study performed in 
Italy (43).  
The relationship between vitamin D deficiency and obesity is still unknown, and 
it is not clear whether vitamin D deficiency causes obesity or the other way around. 
However, a possible mechanism could be that excess fat tissue could absorb and retain 
vitamin D, and thus reduce circulatory vitamin D available to the body (40). The absence 
of vitamin D could also create interference with the functioning of a hormone called 
leptin, which signals the brain when the stomach is full, therefore, stop eating. 
Additionally there is the possibility that overweight people may tend to spend more time 
indoors and receive less ultraviolet rays from sun. 
The association between vitamin D deficiency and weight could also be a result of 
the link between vitamin D and MetS, as overweightness was shown to be a major 
component of MetS. Previous studies have shown an inverse relationship between 
vitamin D concentrations and the prevalence of the metabolic syndrome, including 
insulin resistance, high total cholesterol and triglyceride levels, low HDL cholesterol 
level, and high blood pressure (44, 45, 46). The onset of T2DM, a common consequence 
of metabolic syndrome, has also been associated with vitamin D deficiency in several 
studies (41, 46). This is thought to be because vitamin D has effects on insulin action that 
may impact several pathways important in the development of T2DM (40). 
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The small range of serum 25(OH)D levels within the sample population could 
have contributed to the lack of significant associations detected between vitamin D status 
and the MetS score in this group. Due to the recruitment process of the Nutritional 
Interventions for Age-Related Muscular Function and Strength Losses Study, participants 
who provided baseline data were required to have serum vitamin D levels between 18 
ng/mL and 30 ng/mL at the time of screening. While research has shown that older adults 
tend to have lower serum vitamin D levels, our data may not be entirely representative of 
the older adult population as a whole (21,33). 
Results of this study differ from other recent reports evaluating vitamin D status 
on metabolic syndrome in the elderly. In a study embedded within the Rotterdam Study, 
serum 25(OH)D concentrations were found to be inversely associated with the prevalence 
of MetS (33). This study was a population-based cohort of 3,240 middle-aged and elderly 
adults (median age 71.2 years), free of T2DM at baseline. The association they found 
between vitamin D and MetS appeared to be primarily driven by elevated waist 
circumference, but was also inversely associated with the prevalence of elevated serum 
TG, reduced HDL cholesterol levels, and elevated fasting glucose levels.  
It is interesting to note that no significant association was found between serum 25(OH)D 
and blood pressure in the Rotterdam Study; however, vitamin D has been implicated in 
controlling the production of renin, one of the most important hormones for regulating 
blood pressure (3,7, 34). The results of this study indicated no significant association 
between either SBP or DBP and vitamin D or MetS; however, Table 3. indicates that 
hypertension and android fat mass were the two largest contributing risk factors to MetS 
in this study population. A large majority (75.3%) of the population suffered from blood 
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pressure>135/80 mmHg. Therefore, while high blood pressure was extremely prevalent 
in this population with low vitamin D status, no statistically significant associations 
between the two factors could not be concluded. 
Addional studies have previously found an inverse association between vitamin D 
status and MetS, but were typically observed in younger populations (35, 36, 37, 38). 
Within a population of older adults, the LASA study found a significant association 
between higher serum 25(OH)D (>50 nmol/L) and lower prevalence of MetS. Similar to 
the Rotterdam Study, the LASA study found HDL cholesterol and waist circumference to 
be significant predictors of vitamin D status.  
Furthermore, it is important to point out the variability in data sources utilized for 
calculation of the MetS score. The initial goal was to obtain NHANES data of adults aged 
60 years or older for all five risk factors of MetS in order to develop a comparative 
standard for population. However, data separated out by age or gender was found to be 
unavailable through this dataset. The NHANES database included data from males and 
females aged 8-69 years old. Therefore, BP, FG, HDL cholesterol, and TG standardized 
values were all based off data from the CoLaus study (32). Data from this study was 
collected by a random sample of 6,188 extensively phenotyped Caucasian subjects (3,251 
women and 2,937 men) aged 35 to 75 years living in Lausanne, Switzerland. Because the 
population of the current study is also extensively Caucasian, similar characteristics 
between populations could be expected. Unfortunately, due to the limited amount of large 
population based DEXA results, the comparative standard for android fat mass utilized in 
this study was based off the mean of the 2005-2006 NHANES dataset (31). While this 
limitation was recognized, it is likely that this only resulted in a small variation in the 
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mean value for android fat mass. Thus, when compiled with the other four risk factors 
making up the total overall score, it is probable that this had little impact on the overall 
results. At any rate, it is more representative than utilizing the mean of our own refined 
population of older adults as a comparative standard. It should be mentioned that this 
same dataset was used to determine a cutoff point for the diagnosis of central adiposity 
when determining MetS status within our population as well. 
In regards to the demographic characteristics of our study population, 97% of this 
sample was white with 95% of the population identifying as non-hispanic or latino as 
shown in Table 2. According to NCEP/ATP III guidelines and based on NHANES 2005-
2006 data, a little more than one-third of the adults in the United States meet the criteria 
for MetS diagnosis (39). In an effort to determine the correlates of vitamin D deficiency, 
researchers found that vitamin D deficiency was common in U.S. adults, especially 
among minority groups (40). Using serum 25(OH)D concentrations ≤ 20 ng/mL as a cut 
off, they found that over 80% of black adults, both men and women, would be 
categorized as vitamin D deficient. Compared with white adults, other minorities were 
also at a higher risk for vitamin D deficiency, especially Hispanic men. Because the skin 
pigment melanin absorbs sunlight, people of color are at particularly high risk for vitamin 
D deficiency (22, 40). The association between race and vitamin D deficiency may be 
related to several factors. Sun exposure is the primary determinant of vitamin D status 
and non-whites require more sunlight exposure to obtain adequate vitamin D levels 
because of skin pigmentation. Another possible explanation could be because of the 
different dietary patterns, particularly the intake of dairy products in different population 
groups (13, 14, 40).
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Furthermore, the prevalence of metabolic syndrome also varied by race and 
ethnicity (39). Non-Hispanic black males were less likely than non-Hispanic white males 
to have metabolic syndrome, but non-Hispanic black and Mexican American females 
were more likely than non-Hispanic white females to have it. Among the five diagnostic 
criteria for MetS abdominal obesity, hypertension, and hyperglycemia were the most 
prevalent. Thus the limited racial and ethnic variation within the sample of this study, 
prevented further examination into many of these variables.  
Moreover, this study was based on a one-time measurement of vitamin D, thus it 
could not show the variation of vitamin D concentration during different seasons. The 
two sample t-test conducted evaluating differences between vitamin D levels based on 
month of blood draw was simply a snapshot in time. It in turn tells us more about the 
difference between two people rather than a difference in overall seasonal variation 
within the population. If participants were evaluated overtime seasonal variations would 
likely have been detected; however, due to the nature of the ongoing study it could not be 
analyzed at this time. 
Major Strengths and Limitations 
The strengths of this study were the large sample size, the use of DEXA in the 
evaluation of android and gynoid fat distribution, and the propostion of a collective MetS 
score to determine the severity of metabolic syndrome. An existing issue in clinical 
diagnoiss of MetS is that MetS is simply a compilation of risk factors with no clear 
agreed upon diagnosis. While the NCEP ATP III criteria used in this study is most 
broadly used in the medical field, this diagnosis fails to indicate any degree of severity 
(11). A standardized score that communicates degree of severity to patients could have 
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profound impacts on public comprehension of current disease state, and their motivation 
to comply with health recommendations.  
On the other hand, the cross-sectional design of the study permits only an 
examination of associations between vitamin D and MetS, no causal relationship can be 
established. Furthermore, there is no way to establish whether MetS or low vitamin D 
status preceeded the other. Therefore the question remains, does low vitamin D status 
cause MetS, or does MetS cause low vitamin D status.  
Conclusion 
This study did not find a statistically significant association between low vitamin 
D status and prevalence of MetS as represented by the MetS score likely due to the 
limited range of vitamin D levels within the sample. However, the combination of 
android fat (%), gynoid fat (%), total cholesterol, VLDL cholesterol, and LDL:HDL ratio 
were predictive of the MetS score. While limitations of this study prevented significant 
association between vitamin D and MetS to be detected, previous literature indicates that 
older adults may benefit from higher serum 25(OH)D, especially women who are at 
greater risk for osteoporosis and bone deterioration. However, the causality between 
vitamin D status and MetS still needs to be investigated. Therefore, randomized 
controlled supplementation trials are needed. 
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